Loading clinical trials...
Loading clinical trials...
The Combination of Anlotinib and Immune Checkpoint Inhibitors for Progressed NSCLC Patients With Muti-line Therapy : a PhaseⅠB Clinical Study
Conditions
Interventions
Anlotinib in combination with Immune checkpoint inhibitors
Locations
1
China
The Affiliated Hospital of Qingdao University
Qingdao, China
Start Date
June 1, 2018
Primary Completion Date
October 1, 2020
Completion Date
November 1, 2020
Last Updated
December 17, 2020
NCT06305754
NCT07486219
NCT05098132
NCT06731413
NCT04585750
NCT05987644
Lead Sponsor
The Affiliated Hospital of Qingdao University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions